For last week’s practice question, we quizzed test takers on Rezvoglar insulin. 75% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

RZ takes 30 units of glargine (Lantus) each night. However, when they went to the pharmacy to pick up their prescription, they received glargine insulin Rezvoglar instead of their usual Lantus.

RZ asks how the pharmacy can give them a different brand of insulin without checking first? After addressing their emotional response, you provide the following, most accurate Information.

Answer Choices:

1. Rezvoglar is the generic version of (glargine) Lantus.
2. Rezvoglar is an interchangeable biosimilar insulin.
3. Rezvoglar can not be switched for glargine (Lantus) without provider approval.
4. Rezvoglar is a rapid acting human biosimilar insulin analog

---

Getting to the Best Answer

Answer 1 is incorrect. 12.73% chose this answer, “Rezvoglar is the generic version of (glargine) Lantus.” This is a very tempting answer, but since insulin is a biologic medication, (biologic medications are large, complex molecules, often made from living cells or tissue) the term “generic” is replaced with “biosimilar”. In addition, the better answer below is more accurate, and offers additional information.

Answer 2 is correct. 74.97% of you chose this answer, “Rezvoglar is an interchangeable biosimilar insulin.” YES, GREAT JOB. The FDA just announced that Rezvoglar has also been approved as an interchangeable biosimilar along with Semglee. An “interchangeable biosimilar,” means that pharmacists can substitute a person’s Lantus prescription with these cheaper alternatives without needing to consult the healthcare prescriber.

Answer 3 is incorrect. 9.17% of respondents chose this answer, “Rezvoglar can not be switched for glargine (Lantus) without provider approval.” With recent FDA approval, Rezvoglar is now an “interchangeable biosimilar,” which means that pharmacists can substitute a person’s Lantus prescription with this cheaper alternative without needing to consult the healthcare prescriber.

Finally, Answer 4 is incorrect. 3.13% chose this answer, “Rezvoglar is a rapid-acting human biosimilar insulin analog.” Rezvoglar is the biosimilar of basal insulin glargine.

Thank you so much for reading this “Rationale of the Week”.

Newly Approved Biosimilar Interchangeable Basal Insulin – PocketCard Update

Under basal insulin glargine, there are now 3 biosimilars listed; Basaglar, Semglee and Rezvoglar. The FDA just announced that Rezvoglar has also been approved as an interchangeable biosimilar along with Semglee. An “interchangeable biosimilar,” means that pharmacists can substitute a person’s Lantus prescription with these cheaper alternatives without needing to consult the healthcare prescriber.

Get Your Own PocketCard
These updates are now posted on the latest version of our Insulin PocketCards, which are available for FREE download, or on our CDCES Coach App. You can also purchase your very own 2023 laminated version and they make perfect gifts for team members.

 

---

Want to learn more about this question? Join us for our

Diabetes Fundamentals 2023 Updates | Level 1
$119 | 9+ CEs

Updates air live between Jan 10, 2023-Jan 26, 2023, at 11:30 am PST

This bundle is specifically designed for healthcare professionals who want to learn more about diabetes fundamentals for their clinical practice or for those who are studying for the Certified Diabetes Care and Education Specialist (CDCES) exam.

2023 Webinar Dates

1. January 10, 2023 – Class 1 – Getting to the Nitty Gritty 1.5 CEs
2. January 12, 2023 – Class 2 – Nutrition and Exercise 1.5 CEs
3. January 17, 2023 – Class 3 – Meds Overview for Type 2 – 1.5 CEs
4. January 19, 2023 – Class 4 – Insulin Therapy & Pattern Management 1.5 CEs
5. January 24, 2023 – Class 5 – Goals of Care – 1.5 CEs
6. January 26, 2023 – Class 6 – Hypoglycemia, Sick Days, Monitoring, Foot Care 1.5 CEs

Intended Audience:  This library of critical information is designed for individuals or groups of diabetes specialists, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, and other health care providers interested in staying up to date on current practices of care for people with diabetes and preparing for the CDCES Certification Exam.

 

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on PZ who is upset by a recent diabetes diagnosis. 64% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

PZ is very upset that they were just diagnosed with diabetes and state “I want to get rid of this diabetes”. PZ has a BMI of 35 and elevated LDL cholesterol levels. Both of PZ’s parents had diabetes and died due to complications. 

Based on the newly released ADA/EASD Consensus Statement, which intervention is recommended to get blood sugars to target and possibly lead to type 2 remission?

Answer Choices:

1. Start an SGLT-2 Inhibitor plus metformin
2. Lose 10-15% of current weight
3. Immediately initiate a walking and strength training program.
4. Encourage insulin pump therapy to preserve beta cell function.

---

Getting to the Best Answer

Answer 1 is incorrect. 26.34% chose this answer, “Start an SGLT-2 Inhibitor plus metformin.” This was a juicy answer, but not the best answer. The ADA/EASD consensus statement suggests starting combination therapy for people with an A1C of 8.5% or greater. However, in this case study, there is no information on PZ’s glucose level, therefore we can’t suggest initiating combination diabetes therapy.

Answer 2 is correct. 63.55% of you chose this answer, “Lose 10-15% of current weight.” YES, GREAT JOB. According to the ADA/EASD Consensus Statement, weight reduction as a targeted intervention can dramatically improved outcomes. “Weight loss of 5–10% confers metabolic improvement; weight loss of 10–15% or more can have a disease-modifying effect and lead to remission of diabetes, defined as normal blood glucose levels for 3 months or more in the absence of pharmacological therapy”. Plus, weight loss provides benefits that extend beyond glycemic management to decrease cardiometabolic risk factors and improve quality of life. In addition to referring all people with diabetes to a RD/RDN for MNT and encouraging regular activity, we can also recommend newer pharmacologic agents that not only lower glucose but support weight loss.

Answer 3 is incorrect. 7.50% of respondents chose this answer, “Immediately initiate a walking and strength training program.” While strength training and physical activity are both critical to promote health and improve insulin sensitivity, they will probably not be enough, by themselves, to get PZ’s A1C to target.

Finally, Answer 4 is incorrect. 2.60% chose this answer, “Encourage insulin pump therapy to preserve beta cell function.” While many people with type 2 diabetes are opting to use insulin pump therapy, initiating someone on insulin pump therapy before trying lifestyle and pharmacologic agents is not a recommended approach based on the latest consensus statement.

Thank you so much for reading this “Rationale of the Week”. You can download our Medication PocketCard or join our Webinar below for more information.

---

Want to learn more about this question? Join us for our

Meds for Type 2 Update; New ADA/EASD Consensus Statement
Level 2 | 1.25 CEs

Airs live on Wednesday, December 15th at 11:30 am PST

Plan on joining this exciting webinar that walks participants through the newly released, “Management of Hyperglycemia in Type 2 Consensus Report by the ADA and EASD”.  These updated guidelines will be incorporated into the 2023 ADA Standards of Care, but you can get a early sneak peak by joining Coach Beverly on December 1st, 2022.  She will highlight the revised guidelines with a focus on new elements and exciting changes on how we approach medication management for type 2 diabetes. Together, we will explore clinical factors to consider when determining the best strategy to improve glucose management in people with type 2 diabetes and other co-conditions. There will be a special focus on cardiovascular risk reduction and renal protection and addressing clinical inertia.

Objectives:

1. Describe the role of Diabetes Care and Education Specialists in advocating for optimal therapeutic approaches.
2. Discuss the application of the new ADA/EASD Guidelines to improve glucose and reduce CV and renal risk.
3. List strategies to initiate and adjust oral and injectable therapy using a person-centered approach

Intended Audience:  A great course for health care professionals seeking evidence-based information that improves the quality of life and outcomes.

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on the new ADA/EASD Standards. 56% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

The new ADA /EASD Management of Hyperglycemia in Type 2 Consensus Statement 2022 was just released. 

Which of the following is an accurate recommendation according to these updated guidelines?

Answer Choices:

1. Initiate treatment with metformin for most individuals, including those with cardiovascular disease.
2. If A1C not at target with 2 or more oral agents, add on basal insulin therapy.
3. Avoid the use of SGLT-2 Inhibitors in those with an eGFR of less than 25.
4. Prioritize the use of organ protective medications in those with cardiorenal disease.

---

Getting to the Best Answer

Answer 1 is incorrect. 15.11% chose this answer, Initiate treatment with metformin for most individuals, including those with cardiovascular disease.” In the past, this would have been the best answer, but based on latest guidelines, metformin is no longer the only first treatment. Based on the individual and our risk assessment (ie heart or renal failure or elevated CV risk) we could choose a SGLT-2 or GLP-1 as first line therapy.

Answer 2 is incorrect. 15.01% of you chose this answer, If A1C not at target with 2 or more oral agents, add on basal insulin therapy.” With the guidelines, they strongly suggest starting a GLP-1 RA before starting basal insulin as the first choice if possible. GLP-1 is preferred since insulin therapy is associated with hypoglycemia and weight gain, while the GLP-1’s is associated with weight loss, CV risk reduction and no hypoglycemia.

Answer 3 is incorrect. 13.87% of respondents chose this answer, “Avoid the use of SGLT-2 Inhibitors in those with an eGFR of less than 25.” This is a juicy answer, but the new guidelines encourage the use of SGLT-2 Inhibitors in people with diabetes with a GFR of 20 or greater, stopping SGLT-2 therapy when dialysis is started. Even with stage 3 & 4 kidney failure, SGLT-2’s can effectively slow the progression of kidney disease and improve CV outcomes in people with diabetes.

Finally, Answer 4 is correct. 56.00% chose this answer, Prioritize the use of organ protective medications in those with cardiorenal disease.” YES, GREAT JOB. This is the best answer. We are encouraged to target therapy based on the individual and to protect organs. For people with renal and heart failure, SGLT-2’s are the preferred class and for people with CV disease, starting either a GLP-1 or SGLT-2 decreases risk of major adverse cardiovascular events (MACE). We hope you can join our webinar on December 1st to learn more.

---

Want to learn more about this question? Join us for our

Meds for Type 2 Update; New ADA/EASD Consensus Statement
Level 2 | 1.25 CEs

Airs live on Wednesday, December 1st at 11:30 am PST

Plan on joining this exciting webinar that walks participants through the newly released, “Management of Hyperglycemia in Type 2 Consensus Report by the ADA and EASD”.  These updated guidelines will be incorporated into the 2023 ADA Standards of Care, but you can get a early sneak peak by joining Coach Beverly on December 1st, 2022.  She will highlight the revised guidelines with a focus on new elements and exciting changes on how we approach medication management for type 2 diabetes. Together, we will explore clinical factors to consider when determining the best strategy to improve glucose management in people with type 2 diabetes and other co-conditions. There will be a special focus on cardiovascular risk reduction and renal protection and addressing clinical inertia.

Objectives:

1. Describe the role of Diabetes Care and Education Specialists in advocating for optimal therapeutic approaches.
2. Discuss the application of the new ADA/EASD Guidelines to improve glucose and reduce CV and renal risk.
3. List strategies to initiate and adjust oral and injectable therapy using a person-centered approach

Intended Audience:  A great course for health care professionals seeking evidence-based information that improves the quality of life and outcomes.

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on how Metformin impacts cancer risk. 64% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

JR is taking Metformin 1000mg BID but is worried that it may increase their risk of cancer and is thinking about stopping the metformin. 

Which of the following is an accurate statement regarding metformin, cancer and safety?

Answer Choices:

1. There is research suggesting that metformin may be associated with a decreased risk of certain cancers.
2. People with diabetes have a slightly lower risk of liver and uterine cancers
3. Some brands of metformin were recalled because of an NDMA impurity, so it is best to avoid metformin for now.
4. Metformin does not increase the risk of cancer, but it can negatively impact renal function.

---

Getting to the Best Answer

Answer 1 is correct. 64.40% chose this answer, “There is research suggesting that metformin may be associated with a decreased risk of certain cancers.” YES, this is the best answer, GREAT JOB. Research is showing that metformin decreases risk of DNA replication disruption, improves cellular health and increases telomere length. In addition, it enhances intestinal microbial diversity, decreases inflammation and lowers glucose levels. There are many research studies investigating metformin’s potential for cancer prevention and improvement of treatment outcomes.

Answer 2 is incorrect. 3.17% of you chose this answer, “People with diabetes have a slightly lower risk of liver and uterine cancers.” People with diabetes are actually at higher risk for liver, pancreas and breast cancer. Researchers aren’t sure exactly why, but insulin resistance, extra body weight, and DNA replication disruption in addition to genetics and social determinants of health, all seem to play a part.

Answer 3 is incorrect. 4.52.% of respondents chose this answer, “Some brands of metformin were recalled because of an NDMA impurity, so it is best to avoid metformin for now.” Since the NDMA impurity was recognized, manufacturing processes were improved to prevent future contamination. Metformin is an important treatment option for people living with diabetes.

Finally, Answer 4 is incorrect. 27.90% chose this answer, “Metformin does not increase the risk of cancer, but it can negatively impact renal function.” Metformin does NOT harm the kidneys. As a matter of fact, metformin protects the kidneys by lowering blood sugars and decreasing inflammation. It is true that people with a GFR below 30, need to avoid metformin to prevent lactic acidosis, however this a VERY rare complication. Metformin is the most widely used diabetes medication world-wide and it has an excellent safety profile. Bonus note, metformin ER causes less GI upset and costs the same as the non-extended release version ($4 a month).

Thank you so much for reading this “Rationale of the Week”. You can download our Medication PocketCard, for more information.

---

Want to learn more about this question? Join us for our

Level 4 | Cancer and Diabetes | 1.25 CEs

Recorded & Ready for Viewing!

Diabetes Education Services Online University Courses are an excellent way to study for your exam anytime and anywhere that is convenient for you. You will have immediate access to your courses  for 1 year after your purchase date. Each individual online course includes a: video presentation, podcast, practice test and additional resources.

Patients with cancer often experience hyperglycemia secondary to treatment, which can increase risk of infection and compromise their nutritional status. In addition, recent research has identified the link between diabetes and cancer. Join us to learn more about this unexpected link and treatment strategies for steroid induced hyperglycemia using a case study approach.

Objectives:

1. Discuss the relationship between cancer, hyperglycemia and insulin resistance.
2. State 3 benefits of normalizing glucose levels during chemotherapy.
3. Using a case study approach, discuss strategies to improve glucose levels and quality of life.

Intended Audience: These courses are knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants and other health care providers interested in enhancing their knowledge of diabetes management for people with cancer.

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on basal, bolus and blood transfusions. 62% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

JZ is excited about their A1c of 5.4%. They take bolus insulin 4 times a day, plus basal insulin at night.  To treat their leukemia, JZ receives blood transfusions weekly.

What is your biggest concern?

Answer Choices:

1. Is JZ experiencing lipohypertrophy?
2. Why is JZ on multiple daily doses?
3. Is JZ adjusting insulin for exercise?
4. What is JZ’s fructosamine level?

---

Getting to the Best Answer

Answer 1 is incorrect. 12.71% chose this answer, “Is JZ experiencing lipohypertrophy?” This answer is tempting, but it is not accurate. Lipohypertrophy is a build up of fat at the injection site, often leading to hyperglycemia (not hypoglycemia) since much of the injected insulin is not being absorbed.

Answer 2 is incorrect. 19.91% of you chose this answer, “Why is JZ on multiple daily doses?” Another tempting answer, but is doesn’t address the reason behind the very low A1C. Certainly, we would want to investigate their regimen safety, but this doesn’t get to the intent of the question.

Answer 3 is incorrect. 5.33.% of respondents chose this answer, “Is JZ adjusting insulin for exercise?” Exercise can cause low blood sugar, but does it explain this A1C of 5.4%. JZ is getting blood transfusions to treat leukemia, can that be affecting their A1C?

Finally, Answer 4 is correct. 62.04% chose this answer, “What is JZ’s fructosamine level?” YES, GREAT JOB. For people receiving blood transfusions, A1C is not an accurate indicator of glucose levels, since they get infusions of non glycosylated red blood cells. This means they have new red blood cells mixing with their own glycosylated blood cells which can result in false lows A1C readings. For this situation, a better measurement is the fructosamine level, which measures the sugar coating of protein in the blood for the past 2-3 weeks. Fructosamine accuracy is not impacted by blood transfusions.

Thank you so much for reading this “Rationale of the Week”. You can download our Medication PocketCard below, for more information.

---

Want to learn more about this question? Join us for our

Level 4 | Cancer and Diabetes | 1.25 CEs

Recorded & Ready for Viewing!

Diabetes Education Services Online University Courses are an excellent way to study for your exam anytime and anywhere that is convenient for you. You will have immediate access to your courses  for 1 year after your purchase date. Each individual online course includes a: video presentation, podcast, practice test and additional resources.

Patients with cancer often experience hyperglycemia secondary to treatment, which can increase risk of infection and compromise their nutritional status. In addition, recent research has identified the link between diabetes and cancer. Join us to learn more about this unexpected link and treatment strategies for steroid induced hyperglycemia using a case study approach.

Objectives:

1. Discuss the relationship between cancer, hyperglycemia and insulin resistance.
2. State 3 benefits of normalizing glucose levels during chemotherapy.
3. Using a case study approach, discuss strategies to improve glucose levels and quality of life.

Intended Audience: These courses are knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants and other health care providers interested in enhancing their knowledge of diabetes management for people with cancer.

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on JR’s fear of hypoglycemia. 85% of respondents chose the best answer. GREAT JOB. We want to share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

JR is 26 years old with type 1 diabetes for over a decade.  JR keeps missing appointments and when you finally get a hold of them on the phone, they start crying and say “I am afraid my blood sugars will go too low, so I stopped using my bolus insulin”. They explain that they were too embarrassed to come in and have their data downloaded.

Based on this information, what would be the most helpful approach?

Answer Choices:

1. Provide reassurance and recognize that JR is dealing with childhood trauma.
2. Encourage JR to start using half their usual dose of bolus insulin to get started.
3. Recognize JR’s effort to prevent low blood sugars and explore their feelings.
4. Remind JR that all of the downloaded data and reports are confidential.

---

Getting to the Best Answer

Answer 1 is incorrect. 5.15% chose this answer, “Provide reassurance and recognize that JR is dealing with childhood trauma.” While there is a real possibility that JR experienced childhood trauma, there is no information to support that assumption in the question. However, providing JR with reassurance and helping with problem solving would be very helpful.

Answer 2 is incorrect. 5.36% of you chose this answer, “Encourage JR to start using half their usual dose of bolus insulin to get started.” Although taking half of the usual dose of bolus insulin is certainly better than taking no insulin, it is not a person centered approach. We need to engage JR in determining the best approach.

Answer 3 is correct. 85.84.% of respondents chose this answer, “Recognize JR’s effort to prevent low blood sugars and explore their feelings.” YES, great job, this is the best answer. We want to use a strength based approach and acknowledge that JR is making a big effort to prevent hypoglycemia and stay safe. We also want to recognize JR’s big emotions around hypoglycemia and explore them more closely. Finally, we will encourage JR to identify next steps.

Finally, Answer 4 is incorrect. 3.65% chose this answer, “Remind JR that all of the downloaded data and reports are confidential.” Not the best answer, but it is true that many people may have access to JR’s reports, which can add even more pressure to make sure everything looks good. When we look at JR’s report, we want to make sure we acknowledge the periods where things are going well before we dive into the troubled spots.

Thank you so much for reading this “Rationale of the Week”.

---

Want to learn more about this question? Join our NEW

ReVive 5 Diabetes Training Program

Save $100! Live Virtual Sessions Air July 19 & July 26th

Whether you are a novice or an expert in providing diabetes care, we invite you to attend this exciting training program that provides the essential steps to address diabetes distress combined with an innovative approach to glucose management that will revolutionize your practice.

“ReVive 5” breathes new life into our relationship with diabetes, bringing a fresh perspective to both the person with diabetes and the provider.

Join A Team of Experts – Save $100

Team of Experts: ReVive 5 is taught by a team of 3 Interdisciplinary Experts:

• Lawrence Fisher, Ph.D., ABPP, Professor Emeritus, UCSF
• Susan Guzman, PhD
• Beverly Thomassian, RN, MPH, CDCES, BC-ADM

Accredited Training Program:

• 14.0 CEs – Includes the 7-hour Session ReVive 5 Training Program, Certificate, and 5 FREE bonus courses to supplement content.
• Free Quarterly ReVive 5 Connect – connect with the instructors to help with problem solving for an hour four times a year.
• A comprehensive set of assessment tools, educational materials, log sheets, and resources.

Dates and Times for ReVive Virtual Training

• For your convenience, we have combined the 4 sessions into 2 half days. Same great content.
• July 19 and 26th from 9am to 12:30 pm PST. Space is limited, so save your space today!

Speakers Interviews – Learn more about the ReVive 5 Team

What is the Biggest Takeaway when Addressing Diabetes Distress? – Dr. Susan Guzman

Do you have to be a Mental Health Expert to Tackle Diabetes Distress? – Dr. Lawrence Fisher

Why I Transformed my Approach to Diabetes Self-Management Education- Coach Beverly

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on the best action before starting Tirzepatide (Mounjaro). 67% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

AR is 36 years old with type 2 diabetes and a BMI of over 40.  Current A1C 7.9%, UACR less than 30, and GFR more than 60.  Current diabetes medications include metformin, sitagliptin, and empagliflozin at maximum doses.  AR is prescribed the new dual incretin tirzepatide (Mounjaro) to help improve glucose levels and support weight loss. 

Before starting tirzepatide (Mounjaro), what action do you recommend to the provider?

Answer Choices:

1. Repeat the UACR and GFR to verify kidney function.
2. Stop the sitagliptin.
3. Decrease metformin dose to prevent hypoglycemia.
4. Evaluate thyroid function.

---

Getting to the Best Answer

Answer 1 is incorrect. 11.31% chose this answer, “Repeat the UACR and GFR to verify kidney function.” This is not the best answer because JR has great kidney function, evidenced by a normal UACR and GFR. So we do not need to recheck kidney function before starting this new dual incretin tirzepatide (Mounjaro).

Answer 2 is correct. 67.43% of you chose this answer, “Stop the sitagliptin.” YES, this is the best answer. The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists recommend against combination therapy with a DPP4-inhibitor and a GLP-1 RA due to the lack of evidence that this strategy is beneficial. Initial research combining the two classes, reflect a negligible glucose lowering effect when GLP-1’s and DPP-4’s are combined. Given the approximate average wholesale price for the DPP-4 inhibitor of $434 and GLP-1 RA of $887, using both simultaneously is not cost effective or clinically beneficial.

Answer 3 is incorrect. 4.4.% of respondents chose this answer, “Decrease metformin dose to prevent hypoglycemia.” No need to decrease the metformin dose, since JR is not on any medication class that will cause hypoglycemia.

Finally, Answer 4 is incorrect. 16.82% chose this answer, “Evaluate thyroid function.” This class of medication is not recommended for any person with a history of medullary thyroid tumor. However, we don’t need to draw a TSH to see if this medication is safe, we would simply do a careful history to see if there is a family history of medullary thyroid tumor.

Thank you so much for reading this “Rationale of the Week”. You can download our Medication PocketCard below, for more information.

---

New Injectable – “TwinCretin” on Printed PocketCards

---

Want to learn more about Diabetes Medications?

Virtual DiabetesEd Training Conference | 30+ CEs

Airs October 12-14th, 2022

Join us LIVE for this Virtual Training Conference and enjoy a sense of community!

Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.

Download Course Flyer | Download Schedule

If you are seeking a state-of-the-art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need. This program can also be a great addition to your CDCES or BC-ADM exam study plan.

Team of expert faculty includes:

• Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES – Educator of the Year, 2020
• Coach Beverly Thomassian, RN, MPH, CDCES, BC-ADM
• Ashley LaBrier, MS, RD, CDCES, Diabetes Program Coordinator

---

Two Registration Options

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

For last week’s practice question, we quizzed test takers on ambulatory glucose profile confusion. Only 62% of respondents chose the best answer, which indicates that there was some uncertainty. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

LS is 72 years old with type 2 diabetes and injects insulin 4 times a day. They were started on a CGM device last month and you are looking at the Ambulatory Glucose Profile (AGP) together.  You notice their time in range is 60%, their time above range is 38%, in low range is 2% and their coefficient of variation is less than 36%. 

What is the best response?

Answer Choices:

1. We still need to improve your coefficient of variation.
2. Based on these results, let’s decrease your insulin by 20%.
3. Time in range should be 70% or greater for your age group.
4. This information is going to help with problem solving.

---

Getting to the Best Answer

Answer 1 is incorrect. 11.89% chose this answer, “We still need to improve your coefficient of variation.” This is a juicy answer, but not the best one. If you refer to the Ambulatory Glucose Profile (AGP) below, you will see that the goal for Coefficient of Variation is less than 36%. In this question, LS has coefficient of variation is less than 36%, so they are meeting the target. This measure of glucose variability is important since it informs us of the intensity and duration of glucose levels fluctuations.

Answer 2 is incorrect. 5.26% of you chose this answer, “Based on these results, let’s decrease your insulin by 20%.” This is not the best answer either. Since their time in range of 60% is a little below target and 38% of the time they are above target, LS might actually need some more insulin. Of course, safety is always first, but their low blood sugar range is only 2%, well below the 5% target.

Answer 3 is incorrect. 20.91% of respondents chose this answer, “Time in range should be 70% or greater for your age group.” Another juicy answer, but just like A1C goals, time in range targets are based on the individual and other factors. For a 72 year old on multiple daily injections, 70% time in range may be too aggressive and put them at risk for hypoglycemia. The target time in range is not a “one size fits all” and needs to be customized to the individual. In addition, this statement uses the “should” word, which can evoke feelings of embarrassment or shame. Instead we might say, “Great job tracking your blood sugars. How are you feeling about your progress?

Finally, Answer 4 is correct. 61.94% chose this answer, “This information is going to help with problem solving.” YES, GREAT JOB, this is the best answer. It is person centered, acknowledges their effort and engages LS in participating in problem solving. This comment will definitely increase their feelings of mastery and empowerment.

---

Want to learn more about this topic? 
Dr. Diana Isaacs is providing a fantastic technology update.

Coach Beverly will highlight diabetes language that is empowering.

Virtual DiabetesEd Training Conference | 30+ CEs

Airs October 12-14th, 2022

Join us LIVE for this Virtual Training Conference and enjoy a sense of community!

Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.

Download Course Flyer | Download Schedule

If you are seeking a state-of-the-art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need. This program can also be a great addition to your CDCES or BC-ADM exam study plan.

Team of expert faculty includes:

• Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES – Educator of the Year, 2020
• Coach Beverly Thomassian, RN, MPH, CDCES, BC-ADM
• Ashley LaBrier, MS, RD, CDCES, Diabetes Program Coordinator

---

Two Registration Options

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.